NXL
Nexalin Technology Inc.NASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$7.20M
P/E Ratio
—
EPS
$-0.50
Beta
4.23
52W High
$2.31
52W Low
$0.34
50-Day MA
$0.47
200-Day MA
$0.87
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nexalin Technology Inc.
Nexalin Technology Inc. is a pioneering player in the medical technology sector, specializing in advanced therapies for neurological and psychiatric disorders. The company develops proprietary transcranial electrical stimulation devices that offer non-invasive treatment options for conditions such as anxiety, depression, and substance addiction. With a strong emphasis on cutting-edge research and mental health improvement, Nexalin is positioned to capitalize on the growing demand for innovative healthcare solutions. Its strategic focus on enhancing patient outcomes through technological advancements highlights its potential for substantial growth in the rapidly evolving digital health landscape.
Fundamentals
| Revenue (TTM) | 301,650 |
| Gross Profit (TTM) | 240,270 |
| EBITDA | $-8.37M |
| Operating Margin | -1404.00% |
| Return on Equity | -221.50% |
| Return on Assets | -118.40% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $0.20 |
| Price-to-Book | 1.95 |
| Price-to-Sales (TTM) | 23.88 |
| EV/Revenue | 11.82 |
| EV/EBITDA | 0.02 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 533.00% |
| Shares Outstanding | $20.58M |
| Float | $17.86M |
| % Insiders | 12.49% |
| % Institutions | 5.99% |
Analyst Ratings
Consensus ($4.00 target)
1
Strong BuyData last updated: 4/9/2026